SCHEMBL4634997

SCHEMBL4634997

COc1ccc(C(=O)COc2c(C(=O)O)sc3ccccc23)c(Cl)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 1/20 0.47
PTPN1 P18031 1/20 0.47
MCL1 Q07820 2/20 0.47
MAPT P10636 5/20 0.45
LMNA P02545 2/20 0.45
GAA P10253 2/20 0.45
HPGD P15428 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
TP53 P04637 1/20 0.45
F10 P00742 2/20 0.44
PRSS12 P56730 2/20 0.44
SENP5 Q96HI0 2/20 0.44
SENP2 Q9HC62 2/20 0.44
SENP1 Q9P0U3 2/20 0.44
NPSR1 Q6W5P4 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
BCL2 P10415 1/20 0.43
BCL2L1 Q07817 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4605523 0.91 MAPT (0.43) MAPTLMNAGAAHPGDMEN1
SCHEMBL4634501 0.88 MAPT (0.60) MAPTLMNAGAAHPGDMEN1
SCHEMBL4633954 0.86 MAPT (0.55) PTPN2PTPN1MCL1MAPTLMNA
SCHEMBL4635048 0.85 L3MBTL1 (0.52) PTPN2PTPN1MEN1KMT2ATDP1
SCHEMBL4635019 0.82 MAPT (0.48) MAPTLMNAGAAHPGDMEN1
SCHEMBL4635045 0.77 PTPN1 (0.63) PTPN2PTPN1MCL1LMNAKMT2A
SCHEMBL4635101 0.77 PTPN2 (0.56) PTPN2PTPN1MCL1MAPTLMNA
SCHEMBL4603666 0.77 MAPT (0.52) MAPTLMNAGAAHPGDMEN1
SCHEMBL11844844 0.76 PTPN2 (0.60) PTPN2PTPN1MCL1MAPTLMNA
SCHEMBL4603711 0.76 L3MBTL1 (0.49) MAPTLMNATDP1SENP5SENP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685121-B1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOTHIOPHENE DERIVATIVES MERCK PATENT GMBH (DE) 2008-06-11 EP claimed
EP-1685121-B1 ANTIDIABETIC COMPOUNDS COMPRISING BENZOTHIOPHENE DERIVATIVES MERCK PATENT GMBH (DE) 2008-06-11 EP disclosed
US-7375130-B2 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-05-20 US disclosed
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives MERCK PATENT GMBH (DE) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078178-A1 Antidiabetic compounds comprising benzofuran and benzothiophene derivatives GPR119, INSR, GLP1R PTPN2 2217/4885PTPN1 1650/4885MCL1 3299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.